Key Findings
CordenPharma has announced a multi-million dollar strategic investment to significantly expand its oligonucleotide manufacturing capabilities across its global network. This expansion is designed to meet the surging global demand for complex oligonucleotide active pharmaceutical ingredients (APIs) used in nucleic acid-based medicines (NBMs), including gene therapies, RNAi therapeutics, and antisense oligonucleotides (ASOs).
Technical / Clinical Details
CordenPharma’s expansion plan includes the addition of new synthesis trains, purification equipment, and lyophilization capabilities within its existing facilities. Specifically, it involves the implementation of automated platforms for high-titer oligonucleotide manufacturing, expanding its cGMP (current Good Manufacturing Practice) compliant production scale. This will enable the company to supply a wider range of oligonucleotide APIs with diverse chemical modifications and complex sequences more rapidly, efficiently, and with high quality. The investment is particularly geared towards supporting large-scale Phase 3 clinical trials and commercial production projects, strengthening the company’s supply chain resilience. Newly introduced technologies will also contribute to improved yields and cost reductions, enhancing cost-efficiency for clients.
Background & Context
Nucleic acid-based medicines have become one of the fastest-growing modalities in drug discovery since demonstrating their transformative potential with COVID-19 vaccines. The pipeline for a wide range of diseases, including cancer, neurodegenerative disorders, and infectious diseases, is rapidly expanding, leading to a significant increase in demand for high-purity, complex oligonucleotide API manufacturing services. However, oligonucleotide synthesis is a complex multi-step process requiring specialized chemical expertise and manufacturing facilities. Therefore, experienced CDMOs are becoming indispensable in addressing bottlenecks in this field.
Strategic Significance & Outlook
CordenPharma’s expansion of its oligonucleotide manufacturing capacity holds significant implications for accelerating the development and commercialization of nucleic acid-based medicines. This investment will strengthen the company’s position as a reliable partner for clients seeking to successfully advance their nucleic acid programs throughout their entire lifecycle. The NBM market is projected to continue its robust growth, and CordenPharma’s strategic move will play a central role in shortening the time it takes for next-generation innovative therapies to reach patients, contributing significantly to the overall growth of the industry. This reaffirms that DDS technology is at the forefront of pharmaceutical development.
Source: #
Comments